{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:38:03Z","timestamp":1791437883204,"version":"4.3.3"},"reference-count":35,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["PI20\/00409"],"award-info":[{"award-number":["PI20\/00409"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C&gt;T and ATM c.1236-2A&gt;T) were analyzed in the patients\u2019 plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p &lt; 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients\u2019 outcomes.<\/jats:p>","DOI":"10.3390\/ijms242316578","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:24:13Z","timestamp":1700562253000},"page":"16578","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2792-5316","authenticated-orcid":false,"given":"Raquel","family":"Carrasco","sequence":"first","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"},{"name":"Gen\u00e8tica i Tumors Urol\u00f2gics, Fundaci\u00f3 de Recerca Clinic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain"},{"name":"Departament de Biomedicina, Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Ingelmo-Torres","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"},{"name":"Gen\u00e8tica i Tumors Urol\u00f2gics, Fundaci\u00f3 de Recerca Clinic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7951-9881","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Trullas","sequence":"additional","affiliation":[{"name":"Unitat de Neurobiologia, Institut d\u2019Investigacions Biom\u00e8diques de Barcelona (IIBB\/CSIC\/IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella L.","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"},{"name":"Gen\u00e8tica i Tumors Urol\u00f2gics, Fundaci\u00f3 de Recerca Clinic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Rodr\u00edguez-Carunchio","sequence":"additional","affiliation":[{"name":"Servei d\u2019Anatomia Patol\u00f2gica, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Juez","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Sureda","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"},{"name":"Gen\u00e8tica i Tumors Urol\u00f2gics, Fundaci\u00f3 de Recerca Clinic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-9422","authenticated-orcid":false,"given":"Lourdes","family":"Mengual","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"},{"name":"Gen\u00e8tica i Tumors Urol\u00f2gics, Fundaci\u00f3 de Recerca Clinic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain"},{"name":"Departament de Biomedicina, Facultat de Medicina i Ci\u00e8ncies de la Salut, Universitat de Barcelona (UB), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Laboratori i Servei d\u2019Urologia, Hospital Clinic de Barcelona, 08036 Barcelona, Spain"},{"name":"Gen\u00e8tica i Tumors Urol\u00f2gics, Fundaci\u00f3 de Recerca Clinic Barcelona-Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_2","first-page":"94","article-title":"Effect of Adjuvant Chemotherapy in Locally Advanced Urothelial Carcinoma of the Bladder Treated with Cystectomy","volume":"44","year":"2020","journal-title":"Actas Urol. Esp. (Eng. Ed.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0022-5347(05)67522-2","article-title":"Limitations of Computerized Tomography in Staging Invasive Bladder Cancer before Radical Cystectomy","volume":"163","author":"Paik","year":"2000","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10238-019-00563-w","article-title":"Advances in Liquid Biopsy Using Circulating Tumor Cells and Circulating Cell-Free Tumor DNA for Detection and Monitoring of Breast Cancer","volume":"19","author":"Zhang","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Toledano-Fonseca, M., Cano, M.T., Inga, E., Rodr\u00edguez-Alonso, R., G\u00f3mez-Espa\u00f1a, M.A., Guil-Luna, S., Mena-Osuna, R., de la Haba-Rodr\u00edguez, J.R., Rodr\u00edguez-Ariza, A., and Aranda, E. (2020). Circulating Cell-Free Dna-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Cancers, 12.","DOI":"10.3390\/cancers12071754"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17756","DOI":"10.18632\/oncotarget.24879","article-title":"Circulating Tumor DNA in Early Response Assessment and Monitoring of Advanced Colorectal Cancer Treated with a Multi-Kinase Inhibitor","volume":"9","author":"Vandeputte","year":"2018","journal-title":"Oncotarget"},{"key":"ref_7","first-page":"3911","article-title":"Applications of Liquid Biopsy in Lung Cancer-Diagnosis, Prognosis Prediction, and Disease Monitoring","volume":"10","author":"Luo","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-022-01590-0","article-title":"The Clinical Utility of Dynamic ctDNA Monitoring in Inoperable Localized NSCLC Patients","volume":"21","author":"Yang","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis","volume":"73","author":"Christensen","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41598-018-20282-8","article-title":"Optimized Targeted Sequencing of Cell-Free Plasma DNA from Bladder Cancer Patients","volume":"8","author":"Christensen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2020.05.012","article-title":"Monitoring of Urothelial Cancer Disease Status after Treatment by Digital Droplet PCR Liquid Biopsy Assays","volume":"38","author":"Pritchard","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Carrasco, R., Ingelmo-Torres, M., G\u00f3mez, A., Trullas, R., Rold\u00e1n, F.L., Ajami, T., Moreno, D., Rodr\u00edguez-Carunchio, L., Alcaraz, A., and Izquierdo, L. (2022). Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911732"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00345-022-04061-9","article-title":"Prognostic Implication of TERT Promoter Mutation and Circulating Tumor Cells in Muscle-Invasive Bladder Cancer","volume":"40","author":"Carrasco","year":"2022","journal-title":"World J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early Reduction in CtDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating Tumor DNA in Neoadjuvant-Treated Breast Cancer Reflects Response and Survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tan, M.P., Attard, G., and Huddart, R.A. (2018). Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092568"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"CtDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","article-title":"Serial CtDNA Analysis Predicts Clinical Progression in Patients with Advanced Urothelial Carcinoma","volume":"126","author":"Shohdy","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Crupi, E., de Padua, T.C., Marandino, L., Raggi, D., Dyrskj\u00f8t, L., Spiess, P.E., Sonpavde, G.P., Kamat, A.M., and Necchi, A. (2023). Circulating Tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Eur. Urol. Oncol.","DOI":"10.1016\/j.euo.2023.05.012"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.tranon.2023.101763","article-title":"Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials","volume":"37","author":"Nawaf","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/PO.19.00292","article-title":"Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy","volume":"4","author":"Li","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal Residual Disease Detection Using a Plasma-Only Circulating Tumor DNA Assay in Patients with Colorectal Cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41585-018-0001-5","article-title":"Implications of TERT Promoter Mutations and Telomerase Activity in Urothelial Carcinogenesis","volume":"15","author":"Wezel","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/ijc.31935","article-title":"Combined Genetic and Epigenetic Alterations of the TERT Promoter Affect Clinical and Biological Behavior of Bladder Cancer","volume":"144","author":"Lee","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng.3781","article-title":"Systematic Analysis of Telomere Length and Somatic Alterations in 31 Cancer Types","volume":"49","author":"Barthel","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT Promoter Mutations in Human Cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT Promoter Mutations in Bladder Cancer Affect Patient Survival and Disease Recurrence through Modification by a Common Polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"78890","DOI":"10.18632\/oncotarget.20354","article-title":"Sensitive Droplet Digital PCR Method for Detection of TERT Promoter Mutations in Cell Free DNA from Patients with Metastatic Melanoma","volume":"8","author":"McEvoy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/jgh.15227","article-title":"Prediction of the Prognosis of Advanced Hepatocellular Carcinoma by TERT Promoter Mutations in Circulating Tumor DNA","volume":"36","author":"Hirai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/00365521.2020.1837928","article-title":"TERT Promoter Mutated Circulating Tumor DNA as a Biomarker for Prognosis in Hepatocellular Carcinoma","volume":"55","author":"Oversoe","year":"2020","journal-title":"Scand J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","article-title":"Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma","volume":"5","author":"Isharwal","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16578\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:24Z","timestamp":1760131584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":35,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316578"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316578","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}